IP Library Patent Application 12535268
Patent Application
App. No. 12/535,268

Methods of Preparing Pharmaceutical Compositions Comprising Eslicarbazepine Acetate and Methods of Use

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/535,268
Abstract

The present disclosure relates to the treatment of various diseases and conditions with eslicarbazepine acetate. The present disclosure also relates to the use of eslicarbazepine acetate in a method for reducing or decreasing epileptic seizures in a patient. The present disclosure also relates to a method for increasing the exposure to eslicarbazepine in a patient. The present disclosure also relates to a method of preparing a pharmaceutical composition comprising eslicarbazepine acetate.

Claims (6)

1 - 29 . (canceled)

30 . A method for the treatment of at least one affective disorder or at least one bipolar disorder in a patient in need thereof, comprising administering to the patient a pharmacologically effective amount of eslicarbazepine acetate.

31 . The method according to claim 30 , comprising administering to said patient an amount of eslicarbazepine acetate ranging between about 400 mg and about 2400 mg approximately every 24 hours.

32 . A method for the treatment of at least one manic symptom in a patient in need thereof, comprising administering to the patient a pharmacologically effective amount of eslicarbazepine acetate.

33 . A method for the maintenance treatment of at least one affective disorder or at least one bipolar disorder in a patient in need thereof, comprising administering to the patient a pharmacologically effective amount of eslicarbazepine acetate.

34 . The method according to claim 33 , comprising administering to said patient an amount of eslicarbazepine acetate ranging between about 400 mg and about 2400 mg approximately every 24 hours.

Assignments (1)
CHANGE OF NAME Recorded May 3, 2012
From: PORTELA & C.A., S.A.
To: BIAL-PORTELA & CA, S.A.
Reel/Frame 028148/0131 →